Hoffmann-LA Roche Inc competitors

Marc’s career in pharmaceuticals, which has included periods with Roussel Uclaf, Hoechst Marion Roussel and GlaxoSmithKline (GSK), has given him extensive industry experience, including finance and accounting; corporate strategy and planning; research and development; sales and marketing; business reorganisation; and business development. Marc is a qualified accountant and joined AstraZeneca in 2013, serving as Executive Vice-President, GPPS from June to October 2013. Prior to that, he served as Global Head of Rare Diseases at GSK and (concurrently) Chairman, GSK Japan. He holds an MBA from HEC, Paris and a Bachelor of Law degree from Paris University.

Mr. Gerard J. Michel has served as our Chief Financial Officer, Vice President of Corporate Development and Treasurer, since November 2007. Prior to joining Biodel, Mr. Michel served in various roles at NPS Pharmaceuticals, most recently as its Chief Financial Officer and Vice President of Corporate Strategy. Previously, Mr. Michel was a principal with the consulting firm of Booz-Allen & Hamilton where he evaluated and solved strategic and operational issues for healthcare clients. Mr. Michel also served in marketing, sales, and corporate development positions, both domestic and international with Lederle Labs. Mr. Michel received an M.S. in microbiology and an M.B.A., both from the University of Rochester.

Hervé Hoppenot joined Incyte in 2014 as President and Chief Executive Officer, and was appointed Chairman of the Board of Directors in 2015. During Mr. Hoppenot’s tenure, the Company has tripled the number of clinical candidates in its portfolio, expanding beyond oncology to include research and development in inflammation & autoimmunity. Under his leadership, revenue has increased by over 400 percent, which includes the addition of two new revenue streams; and, with a goal to deliver medicines to patients worldwide, the Company has expanded geographically beyond the U.S. to include operations in 10 EU countries and Japan. Prior to joining Incyte, Mr. Hoppenot was the President of Novartis Oncology. Prior to joining Novartis in 2003, Mr. Hoppenot started his career in 1983 with Rhone Poulenc, later known as Aventis, where he served in several senior roles of increasing responsibility, including Vice President of Oncology and Head of the U.S. Oncology business unit. Mr. Hoppenot holds a diploma from ESSEC Business School.

Reshma Kewalramani (born 1973), is the president and chief executive officer of Vertex Pharmaceuticals, a biotechnology company based in Boston, Massachusetts, as of April 1, 2020. She is the first female CEO of a large US biotech company. She was previously the chief medical officer and vice president of global medicines development and medical affairs at Vertex.

Stephan Kutzer is a Chief Executive Officer at CAMBRIDGE MAJOR LABORATORIES and Chief Executive Officer at AAIPharma Services. He has worked as COO:Pharma & Biotech Mkt Segment at Lonza America Inc., Head:Performance Chemicals at Lonza America Inc., and Assistant Production Manager at Lonza America Inc.. Stephan attended Technical University of Munich.

John Ratliff served as Chief Executive Officer of Covance Drug Development, the world’s most comprehensive drug development company. He is a highly respected biopharmaceutical leader, with extensive experience in increasingly influential roles in the industry. In 2018, Ratliff was appointed Chairman for the Association of Clinical Research Organizations. Previously John was president and CEO of HUYA Bioscience International. His healthcare industry experience also includes almost 10 years at Quintiles, the world’s largest provider of product development and integrated healthcare services, where he served as Chief Financial Officer before becoming President and Chief Operating Officer. He was a member of the Quintiles board of directors. Prior roles throughout his career included CFO at Acterna, a provider of communications test solutions for telecommunications and cable network operators, and positions of increasing responsibility during his 19-year tenure at IBM.

Ronald Piervincenzi is a Chief Executive Officer at United States Pharmacopeia and is based in Rockville, Maryland. He has worked as Principal at McKinsey & Company and VP Development Sciences Business Strategy at BIOGEN INC.. Ronald studied at Hofstra University between 1989 and 1993 and Duke University between 1993 and 2000.

Richard L Feinstein is a VP:Finance/CFO at ENZON PHARMACEUTICALS, INC.; Chief Financial Officer at USA Fitness Corps; and Board Member at USA Fitness Corps and is based in Greater New York City Area. He has worked as VP:Finance/Principal Financial Ofcr at ENZON PHARMACEUTICALS, INC.; Partner at KPMG; and CFO/Consultant at ImageProtect. Richard works or has worked as MEMBER at Association For A Better New York. He studied at Pace University.